Microcrack frequency and bone remodeling in postmenopausal osteoporotic women on long-term bisphosphonates: A bone biopsy study

被引:111
作者
Chapurlat, Roland D. [1 ]
Arlot, Monique [1 ]
Burt-Pichat, Brigitte [1 ]
Chavassieux, Pascale [1 ]
Roux, Jean Paul [1 ]
Portero-Muzy, Nathalie [1 ]
Delmas, Pierre D. [1 ]
机构
[1] INSERM, Res Unit 831, F-69437 Lyon 03, France
关键词
osteoporosis; microcracks; bispbosphonates; alendronate; risedronate;
D O I
10.1359/JBMR.070609
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: Animal studies suggest that bisphosphonates (BPS) could increase microdamage frequency in a dose-dependent manner, caused by excessively suppressed bone turnover. However, there is limited data in humans receiving BP therapeutic doses for >3 yr. Materials and Methods: We measured microcrack frequency and histomorphometry parameters on transiliac bone biopsies in 50 postmenopausal osteoporotic women (mean age = 68 yr) who had received BP therapy (3 on intravenous pamidronate, 37 on oral alendronate, and 10 on oral risedronate) for at least 3 yr (mean treatment duration = 6.5 yr). We compared these results with transiliac bone biopsies obtained from 12 cadavers. We used bulk staining with green calcein as a fluorochrome. The microcracks were quantified in three 100-mu m-thick sections using optic microscopy and were confirmed by laser confocal microscopy. Microcrack frequency (number of microcracks/mm(2) of bone tissue) was compared between treated women and controls using nonparametric tests. We also explored predictors of microcrack frequency, including age, duration of BP therapy, and activation frequency. Results: Among treated women, cancellous bone microcrack frequency was low (mean, 0.13 microcracks/mm(2)) and did not differ significantly from that observed in controls (0.05 microcracks/mm(2); P = 0.59). Of note, 54% of the treated women and 58% of the controls had no observable Microcracks. There was no association between microcrack frequency and the duration of BP therapy (for microcrackS/mm(2) and duration, Spearman r = 0.04, p = 0.80) and between patients' ages and the number of microcracks (Spearman r = -0.09, p = 0.61). Although bone remodeling parameters were suppressed in treated women, we found no relationship between microcrack density and activation frequency (Spearman r = -0.003, p = 0.99). Also, microcrack frequency was not increased in women with prevalent vertebral fracture compared with those without fractures. Conclusions: Among postmenopausal osteoporotic women on long-term BPS, microcrack frequency in the iliac bone is low, despite a marked reduction of bone turnover.
引用
收藏
页码:1502 / 1509
页数:8
相关论文
共 47 条
[1]  
Allen MR, 2006, J BONE MINER RES, V21, pS70
[2]   Alterations in canine vertebral bone turnover, microdamage accumulation, and biomechanical properties following 1-year treatment with clinical treatment doses of risedronate or alendronate [J].
Allen, Matthew R. ;
Iwata, Ken ;
Phipps, Roger ;
Burr, David B. .
BONE, 2006, 39 (04) :872-879
[3]  
Arlot M E, 1990, Osteoporos Int, V1, P41, DOI 10.1007/BF01880415
[4]   Intracortical remodeling in adult rat long bones after fatigue loading [J].
Bentolila, V ;
Boyce, TM ;
Fyhrie, DP ;
Drumb, R ;
Skerry, TM ;
Schaffler, MB .
BONE, 1998, 23 (03) :275-281
[5]   Effects of continuing or stopping alendronate after 5 years of treatment - The Fracture Intervention Trial long-term extension (FLEX): A randomized trial [J].
Black, Dennis M. ;
Schwartz, Ann V. ;
Ensrud, Kristine E. ;
Cauley, Jane A. ;
Levis, Silvina ;
Quandt, Sara A. ;
Satterfield, Suzanne ;
Wallace, Robert B. ;
Bauer, Douglas C. ;
Palermo, Lisa ;
Wehren, Lois E. ;
Lombardi, Antonio ;
Santora, Arthur C. ;
Cummings, Steven R. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 296 (24) :2927-2938
[6]   Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures [J].
Black, DM ;
Cummings, SR ;
Karpf, DB ;
Cauley, JA ;
Thompson, DE ;
Nevitt, MC ;
Bauer, DC ;
Genant, HK ;
Haskell, WL ;
Marcus, R ;
Ott, SM ;
Torner, JC ;
Quandt, SA ;
Reiss, TF ;
Ensrud, KE .
LANCET, 1996, 348 (9041) :1535-1541
[7]   Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women [J].
Boivin, GY ;
Chavassieux, PM ;
Santora, AC ;
Yates, J ;
Meunier, PJ .
BONE, 2000, 27 (05) :687-694
[8]   Ten years' experience with alendronate for osteoporosis in postmenopausal women [J].
Bone, HG ;
Hosking, D ;
Devogelaer, J ;
Tucci, JR ;
Emkey, RD ;
Tonino, RP ;
Rodriguez-Portales, JA ;
Downs, RW ;
Gupta, J ;
Santora, AC ;
Liberman, UA .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (12) :1189-1199
[9]   Effect of osteoporosis treatments on risk of non-vertebral fractures: review and meta-analysis of intention-to-treat studies [J].
Boonen, S ;
Laan, RF ;
Barton, IP ;
Watts, NB .
OSTEOPOROSIS INTERNATIONAL, 2005, 16 (10) :1291-1298
[10]   ALTERATIONS TO THE EN-BLOC BASIC FUCHSIN STAINING PROTOCOL FOR THE DEMONSTRATION OF MICRODAMAGE PRODUCED IN-VIVO [J].
BURR, DB ;
HOOSER, M .
BONE, 1995, 17 (04) :431-433